Clearpoint Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>CN</div>
CLPT -- USA Stock  

USD 23.42  1.78  8.23%

In spite of comparatively unfluctuating basic indicators, Clearpoint Neuro unveiled solid returns over the last few months and may actually be approaching a breakup point. We currently estimate Clearpoint Neuro as overvalued. The real value is approaching 18.26 per share.
Published over a month ago
View all stories for Clearpoint Neuro | View All Stories
Does Clearpoint Neuro (NYSEMKT:CLPT) have stable basic indicators based on the newest gain?
Our investment recommendation module complements current analysts and expert consensus on Clearpoint Neuro. It analyzes the firm potential to grow using all fundamental, technical, and market related data available at the time. This firm dividends can provide a clue to the current value of the stock. Clearpoint Neuro is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Clearpoint Neuro income statement, its balance sheet, and the statement of cash flows. Potential Clearpoint Neuro investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Clearpoint Neuro investors may use each financial statement separately, they are all related. The changes in Clearpoint Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Clearpoint Neuro's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Clearpoint Neuro fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Clearpoint Neuro performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Clearpoint Neuro shares is the value that is considered the true value of the share. If the intrinsic value Clearpoint is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Clearpoint Neuro.
Please read more on our fundamental analysis page.

What is Clearpoint Asset Breakdown?

Clearpoint Neuro reports assets on its Balance Sheet. It represents the amount of Clearpoint resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Clearpoint volatility, please check the breakdown of all its fundamentals

Are Clearpoint Neuro Earnings Expected to grow?

The future earnings power of Clearpoint Neuro involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Clearpoint Neuro factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Clearpoint Neuro stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Clearpoint expected earnings.

Clearpoint Neuro Gross Profit

Clearpoint Neuro Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Clearpoint Neuro previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Clearpoint Neuro Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

A Deeper Perspective

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Clearpoint Neuro is not uncomon. Institutional investors typically avoid acquiring a high percentage of Clearpoint Neuro stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Clearpoint is distributed among investors.

Ownership Allocation

Clearpoint Neuro holds a total of sixteen million eight hundred seventy thousand outstanding shares. Clearpoint Neuro retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors65.12
 2018 2019 2020 2021 (projected)
Interest Expense980.38 K955.17 K859.65 K1.01 M
Gross Profit4.92 M7.38 M8.49 M9.16 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clearpoint Neuro has an asset utilization ratio of 126.44 percent. This implies that the company is making $1.26 for each dollar of assets. An increasing asset utilization means that Clearpoint Neuro is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
10.3 M
Current Assets10.33 Million82.19
Assets Non Current1.38 Million11.02

Our perspective of the newest Clearpoint Neuro gain

Newest market risk adjusted performance is at -1.61. Clearpoint Neuro shows above-average downside volatility for the selected time horizon. We advise investors to inspect Clearpoint Neuro further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Clearpoint Neuro future alpha.

Our Takeaway on Clearpoint Neuro Investment

Whereas many other companies under the medical devices industry are still a bit expensive, Clearpoint Neuro may offer a potential longer-term growth to private investors. To summarize, as of the 23rd of January 2021, our research shows that Clearpoint Neuro is a rather somewhat reliable investment opportunity with a close to average probability of distress in the next two years. From a slightly different view, the entity currently appears to be overvalued. Our primary 30 days buy vs. sell advice on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Clearpoint Neuro. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to